```
=> d his

     (FILE 'HOME' ENTERED AT 10:22:40 ON 11 MAY 2005)

     FILE 'CAPLUS' ENTERED AT 10:34:24 ON 11 MAY 2005
L1             1 S US6586455/PN
                 SELECT L1 1 RN
L2         58943 S E1-E9

     FILE 'REGISTRY' ENTERED AT 10:38:36 ON 11 MAY 2005
L3             1 S 110-00-9/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 10:38:54 ON 11 MAY 2005
L4             1 S 153559-49-0/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 10:41:23 ON 11 MAY 2005
L5             1 S 153559-76-3/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 10:42:30 ON 11 MAY 2005
L6             1 S 122320-73-4/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 10:44:35 ON 11 MAY 2005
L7             1 S 111025-46-8/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 10:48:22 ON 11 MAY 2005
L8             1 S 97322-87-7/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'CAPLUS' ENTERED AT 10:49:24 ON 11 MAY 2005
L9          3215 S L8 OR L7 OR L6 OR NOSCAL OR REZULIN OR ROMGLIZONE OR TROGLITA
L10           87 S L9(L)((BREAST OR LEUKEM? OR COLON? OR PROSTATE)(S)(CANCER? OR
L11            0 S L10 NOT PY>=1996
L12           43 S L10 NOT PY>=2003

=> s l9(l)(breast or leukem? or colon? or prostate or cancer? or neoplas? or tumor? or carcino?
or ?sarcoma#)
TRUNCATION COMBINATION NOT VALID '?SARCOMA#'
Simultaneous left and right truncation is not possible for this
combination of truncation symbols.  For more information about
truncation in the current file, enter "HELP TRUNCATION".

=> s l9(l)(breast or leukem? or colon? or prostate or cancer? or neoplas? or tumor? or carcino?
or ?sarcoma)
         60700 BREAST
           505 BREASTS
         60881 BREAST
                 (BREAST OR BREASTS)
         94650 LEUKEM?
        137357 COLON?
         40825 PROSTATE
          1255 PROSTATES
         40931 PROSTATE
                 (PROSTATE OR PROSTATES)
        257906 CANCER?
        407959 NEOPLAS?
        389645 TUMOR?
        220528 CARCINO?
```

371

369.

```
        45163 ?SARCOMA
L13       428 L9(L)(BREAST OR LEUKEM? OR COLON? OR PROSTATE OR CANCER? OR
              NEOPLAS? OR TUMOR? OR CARCINO? OR ?SARCOMA)

=> s l13 not py>=2000
      5429777 PY>=2000
L14        55 L13 NOT PY>=2000

=> s l13 not py>=2004
      1528329 PY>=2004
L15       294 L13 NOT PY>=2004

=> d ibib
```

```
=> s us6646008/pn
L1            1 US6646008/PN

=> select l1
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
E1 THROUGH E11 ASSIGNED

=> s e1-e11
          3141 41598-07-6/BI
           247 60203-57-8/BI
           164 102121-60-8/BI
          9575 110-00-9/BI
           160 153559-49-0/BI
           103 153559-76-3/BI
          1331 5300-03-8/BI
         15402 59-67-6/BI
         30987 65-85-0/BI
           172 87893-54-7/BI
           501 87893-55-8/BI
L2       60305 (41598-07-6/BI OR 60203-57-8/BI OR 102121-60-8/BI OR 110-00-9/BI
                OR 153559-49-0/BI OR 153559-76-3/BI OR 5300-03-8/BI OR 59-67-6/
               BI OR 65-85-0/BI OR 87893-54-7/BI OR 87893-55-8/BI)
```

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **111025-46-8** REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
, (±)-
OTHER NAMES:
CN 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
CN Pioglitazone
CN U 72107
FS 3D CONCORD
DR 105355-27-9, 198077-89-3
MF C19 H20 N2 O3 S
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS,
IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT,
PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP
(Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
study); BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); PREP (Preparation); PROC (Process); PRP (Properties); RACT
(Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study); PREP (Preparation); PRP (Properties); USES (Uses)



Compound in claim 5

Et

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

934 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
944 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **122320-73-4** REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
CN 5-[[4-[2-[N-Methyl-N-(2-pyridyl)amino]ethoxy]phenyl]methyl]thiazolidine-2,4-dione
CN BRL 49653
CN Rosiglitazone
CN Rosiglizole
FS 3D CONCORD
MF C18 H19 N3 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties)



Instant Compound in claim 5 formed.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1126 REFERENCES IN FILE CA (1907 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1136 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **97322-87-7** REGISTRY
CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN CI 991
CN CS 045
CN GR 92132X
CN Noscal
CN Rezulin
CN Romglizone
CN Troglitazone
FS 3D CONCORD
DR 259223-65-9
MF C24 H27 N O5 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process); USES (Uses)



compound in claim 5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1372 REFERENCES IN FILE CA (1907 TO DATE)
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1379 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **153559-76-3** REGISTRY
CN 3-Pyridinecarboxylic acid, 6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN AGN 192620
CN ALRT 268
CN CD 3127
CN LG 100268
CN LG 268
CN LGD 100268
CN LGD 1268
FS 3D CONCORD
DR 197730-94-2, 262615-35-0, 263723-53-1, 309956-42-1
MF C24 H29 N O2
SR CA
LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)



Compound in claim 12

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

103 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
103 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **153559-49-0** REGISTRY
CN Benzoic acid, 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Bexarotene
CN LG 100069
CN LG 1069
CN LG 69
CN LG 69 (retinoid)
CN LGD 1069
CN RO 26-4455
CN SR 11247
CN Targret
CN Targretin
CN Targretyn
CN Targrexin
FS 3D CONCORD
MF C24 H28 O2
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CIN, DIOGENES, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study)



compound claim 13

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

162 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
163 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L20 ANSWER 34 OF 52 USPATFULL on STN
AN 1999:141993 USPATFULL
TI Methods for treating proliferative and inflammatory skin diseases
IN Pershadsingh, Harrihar A., 404 Windsor Park Dr., Bakersfield, CA, United States 93311
PI US 5981586 19991109
AI US 1998-84037 19980522 (9)
PRAI US 1997-47550P 19970523 (60)
DT Utility
FS Granted
LN.CNT 732
INCL INCLM: 514/543.000
INCLS: 514/571.000
NCL NCLM: 514/543.000
NCLS: 514/571.000
IC [6]
ICM: A61K031-235
ICS: A61K031-19
EXF 514/543; 514/571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 35 OF 52 USPATFULL on STN
AN 1999:132827 USPATFULL
TI Use of thiazolidinedione derivatives in the treatment of anovulation, hyperandrogenism and hirsutism
IN Antonucci, Tammy, Thousand Oaks, CA, United States
Lockwood, Dean, Ann Arbor, MI, United States
Norris, Rebecca, Kewadin, MI, United States
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)
PI US 5972944 19991026
AI US 1998-124707 19980729 (9)
RLI Division of Ser. No. US 1997-868608, filed on 4 Jun 1997 which is a continuation-in-part of Ser. No. US 1997-856987, filed on 15 May 1997, now patented, Pat. No. US 5874454 which is a continuation-in-part of Ser. No. US 1996-763286, filed on 10 Dec 1996, now abandoned which is a division of Ser. No. US 1995-469398, filed on 6 Jun 1995, now patented, Pat. No. US 5602133 which is a division of Ser. No. US 1994-292585, filed on 23 Aug 1994, now patented, Pat. No. US 5457109 which is a continuation-in-part of Ser. No. US 1993-122251, filed on 15 Sep 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1312
INCL INCLM: 514/252.000
INCLS: 514/256.000; 514/342.000; 514/360.000; 514/369.000
NCL NCLM: 514/342.000
NCLS: 514/256.000; 514/360.000; 514/369.000
IC [6]
ICM: A61K031-425
EXF 514/252; 514/256; 514/342; 514/360; 514/369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 36 OF 52 USPATFULL on STN
AN 1999:128534 USPATFULL
TI Method for the prevention of coronary artery spasm
IN Kanda, Iwao, 1617 Via Margarita, Rancho Pales Verdes Estates, CA, United States 40206
PI US 5968918 19991019
AI US 1997-953340 19971017 (8)
DT Utility
FS Granted
LN.CNT 336
INCL INCLM: 514/176.000
INCLS: 514/177.000; 514/178.000; 514/369.000; 514/652.000
NCL NCLM: 514/176.000
NCLS: 514/177.000; 514/178.000; 514/369.000; 514/652.000

IC [6]
ICM: A61K031-58
EXF 514/176; 514/177; 514/178; 514/652; 514/369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 37 OF 52 USPATFULL on STN
AN 1999:121364 USPATFULL
TI Spiro-substituted azacycles as modulators of chemokine receptor activity
IN Mills, Sander G., Scotch Plains, NJ, United States
Maccoss, Malcolm, Freehold, NJ, United States
Springer, Martin S., Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5962462 19991005
AI US 1997-989947 19971212 (8)
PRAI US 1996-32735P 19961213 (60)
US 1996-33558P 19961220 (60)
DT Utility
FS Granted
LN.CNT 6786
INCL INCLM: 514/278.000
INCLS: 514/277.000; 546/015.000; 546/016.000; 546/017.000; 546/018.000
NCL NCLM: 514/278.000
NCLS: 514/277.000; 546/015.000; 546/016.000; 546/017.000; 546/018.000
IC [6]
ICM: A61K031-44
ICS: A61K031-435; C07D209-54; C07D209-56
EXF 546/17; 546/18; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 38 OF 52 USPATFULL on STN
AN 1999:81848 USPATFULL
TI Use of PPARγ agonists for inhibition of inflammatory cytokine production
IN Seed, Brian, Boston, MA, United States
Jiang, Chengyu, Boston, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5925657 19990720
AI US 1997-878406 19970618 (8)
DT Utility
FS Granted
LN.CNT 488
INCL INCLM: 514/369.000
INCLS: 514/370.000; 514/340.000; 514/366.000; 514/365.000
NCL NCLM: 514/369.000
NCLS: 514/340.000; 514/365.000; 514/366.000; 514/370.000
IC [6]
ICM: A01N043-78
ICS: A61K031-425
EXF 514/369; 514/370; 514/340; 514/366; 514/365
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 39 OF 52 USPATFULL on STN
AN 1999:75638 USPATFULL
TI Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
IN Lohray, Vidya Bhushan, Hyderabad, India
Lohray, Braj Bhushan, Hyderabad, India
Rao, Paraselli Bheema, Hyderabad, India
Alla, Sekar Reddy, Hyderabad, India
Ramanujam, Rajagopalan, Hyderabad, India
Chakrabarti, Ranjan, Hyderabad, India
PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)
Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)
PI US 5919782 19990706
AI US 1997-851447 19970505 (8)
RLI Continuation-in-part of Ser. No. US 1996-687840, filed on 26 Jul 1996,

now patented, Pat. No. US 5801173
PRAI IN 1996-72396 19960506
DT Utility
FS Granted
LN.CNT 2141
INCL INCLM: 514/252.000
INCLS: 514/318.000; 514/342.000; 514/369.000; 544/364.000; 546/194.000; 546/280.000; 548/183.000
NCL NCLM: 514/254.020
NCLS: 514/318.000; 514/342.000; 514/369.000; 544/364.000; 546/194.000; 546/269.700; 548/183.000
IC [6]
ICM: C07D417-12
ICS: A61K031-425
EXF 588/183; 544/364; 546/194; 546/280; 514/252; 514/318; 514/342; 514/369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 40 OF 52 USPATFULL on STN
AN 1999:75632 USPATFULL
TI Substituted aminoquinolines as modulators of chemokine receptor activity
IN Hagmann, William K., Westfield, NJ, United States
Springer, Martin S., Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5919776 19990706
AI US 1997-993494 19971218 (8)
DT Utility
FS Granted
LN.CNT 1808
INCL INCLM: 514/159.000
INCLS: 514/160.000; 514/161.000; 514/162.000; 514/163.000; 514/167.000
NCL NCLM: 514/159.000
NCLS: 514/160.000; 514/161.000; 514/162.000; 514/163.000; 514/167.000
IC [6]
ICM: A61K031-47
ICS: A61K031-475; A61K031-49
EXF 514/159; 514/160; 514/161; 514/162; 514/163; 514/167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 41 OF 52 USPATFULL on STN
AN 1999:53646 USPATFULL
TI Composition, food product and uses of 3-guanidinopropionic acid
IN Meglasson, Martin D., Kalamazoo, MI, United States
PA Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 5900435 19990504
WO 9303724 19930304
AI US 1994-196250 19940224 (8)
WO 1992-US6776 19920819
19940224 PCT 371 date
19940224 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1991-751239, filed on 26 Aug 1991
And a continuation-in-part of Ser. No. US 1991-750559, filed on 26 Aug 1991, now abandoned
DT Utility
FS Granted
LN.CNT 821
INCL INCLM: 514/565.000
INCLS: 514/866.000; 514/909.000; 426/330.000; 426/330.500
NCL NCLM: 514/565.000
NCLS: 426/330.000; 426/330.500; 514/866.000; 514/909.000
IC [6]
ICM: A61K031-195
ICS: A23L001-00
EXF 514/330; 514/369; 514/565; 514/592; 514/909; 514/866; 426/330; 426/330.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 42 OF 52 USPATFULL on STN
AN 1999:40449 USPATFULL

TI Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
IN Lohray, Vidya Bhushan, Hyderabad, India
Lohray, Braj Bhushan, Hyderabad, India
Bajji, Ashok Channaveerappa, Hyderabad, India
Alla, Sekar Reddy, Hyderabad, India
Ramanujam, Rajagopalan, Hyderabad, India
Chakrabarti, Ranjan, Hyderabad, India
PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)
Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)
PI US 5889032 19990330
AI US 1997-851448 19970505 (8)
PRAI IN 1996-82196 19960506
DT Utility
FS Granted
LN.CNT 2490
INCL INCLM: 514/369.000
INCLS: 514/255.000; 514/320.000; 514/342.000; 514/343.000; 514/364.000; 514/376.000; 514/414.000; 514/422.000; 544/369.000; 544/373.000; 544/376.000; 546/196.000; 546/269.700; 546/276.400; 548/144.000; 548/183.000; 548/227.000; 548/468.000; 548/525.000
NCL NCLM: 514/369.000
NCLS: 514/254.020; 514/254.030; 514/320.000; 514/342.000; 514/343.000; 514/364.000; 514/376.000; 514/414.000; 514/422.000; 544/369.000; 544/373.000; 544/376.000; 546/196.000; 546/269.700; 546/276.400; 548/144.000; 548/183.000; 548/227.000; 548/468.000; 548/525.000
IC [6]
ICM: A61K031-425
ICS: A61K031-395; C07D277-34; C07D417-02
EXF 514/255; 514/320; 514/342; 514/343; 514/364; 514/369; 514/376; 514/414; 514/422; 544/369; 544/373; 544/376; 546/196; 546/269.7; 546/276.4; 548/144; 548/183; 548/227; 548/468; 548/525
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 43 OF 52 USPATFULL on STN
AN 1999:40442 USPATFULL
TI Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
IN Lohray, Vidya Bhushan, Hyderabad, India
Lohray, Braj Bhushan, Hyderabad, India
Alla, Sekar Reddy, Hyderabad, India
Ramanujam, Rajagopalan, Hyderabad, India
Chakrabarti, Ranjan, Hyderabad, India
PA Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)
Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)
PI US 5889025 19990330
AI US 1997-851450 19970505 (8)
DT Utility
FS Granted
LN.CNT 1692
INCL INCLM: 514/326.000
INCLS: 514/227.800; 514/235.500; 514/236.800; 514/237.200; 514/255.000; 514/363.000; 514/364.000; 514/369.000; 514/376.000; 544/060.000; 544/133.000; 544/367.000; 546/207.000; 546/208.000; 546/209.000; 546/210.000; 548/142.000; 548/144.000; 548/183.000; 548/226.000
NCL NCLM: 514/326.000
NCLS: 514/227.800; 514/235.500; 514/236.800; 514/237.200; 514/249.000; 514/252.050; 514/255.050; 514/264.110; 514/266.100; 514/266.210; 514/363.000; 514/364.000; 514/369.000; 514/376.000; 544/060.000; 544/133.000; 544/367.000; 546/207.000; 546/208.000; 546/209.000; 546/210.000; 548/142.000; 548/144.000; 548/183.000; 548/226.000
IC [6]
ICM: A61K031-445
ICS: C07D417-10; C07D417-12
EXF 544/60; 544/133; 544/367; 546/207; 546/208; 546/209; 546/210; 548/142; 548/144; 548/183; 548/226; 514/227.8; 514/235.5; 514/236.8; 514/237.2;

514/255; 514/326; 514/363; 514/364; 514/369; 514/376
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 44 OF 52 USPATFULL on STN
AN 1999:37111 USPATFULL
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan, Hyderabad, India
Lohray, Braj Bhushan, Hyderabad, India
Paraselli, Rao Bheema, Hyderabad, India
PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)
Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)
PI US 5885997 19990323
AI US 1996-777627 19961231 (8)
PRAI IN 1996-115096 19960701
DT Utility
FS Granted
LN.CNT 1914
INCL INCLM: 514/256.000
INCLS: 514/269.000; 514/258.000; 544/253.000; 544/298.000; 544/311.000; 544/316.000
NCL NCLM: 514/256.000
NCLS: 514/266.200; 514/269.000; 544/253.000; 544/298.000; 544/311.000; 544/316.000
IC [6]
ICM: C07D417-12
ICS: A61K031-425
EXF 544/253; 544/298; 544/311; 544/316; 514/256; 514/258; 514/269
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 45 OF 52 USPATFULL on STN
AN 1999:27182 USPATFULL
TI Glutamine: fructose-6-phosphate amidotransferase, its production and use
IN Nishi, Kazunori, 16-1-402 Namiki 4-chome, Tsukuba, Ibaraki, Japan
Hikichi, Yukiko, 21-2-1-504, Matsushiro 4-chome, Tsukuba, Ibaraki, Japan
Shintani, Yasushi, 7-9-703, Kasuga 1-chome, Tsukuba, Ibaraki, Japan 305
PI US 5876713 19990302
AI US 1997-911445 19970812 (8)
PRAI JP 1996-213944 19960813
DT Utility
FS Granted
LN.CNT 3620
INCL INCLM: 424/094.500
INCLS: 514/012.000; 435/193.000
NCL NCLM: 424/094.500
NCLS: 435/193.000; 514/012.000
IC [6]
ICM: C12N009-10
ICS: A61K038-45
EXF 435/193; 424/94.5; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 46 OF 52 USPATFULL on STN
AN 1999:24672 USPATFULL
TI Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
IN Antonucci, Tammy, Thousand Oaks, CA, United States
Lockwood, Dean, Ann Arbor, MI, United States
Norris, Rebecca, Kewadin, MI, United States
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)
PI US 5874454 19990223
AI US 1997-856987 19970515 (8)
DT Utility
FS Granted
LN.CNT 1217

INCL INCLM: 514/369.000
INCLS: 514/342.000
NCL NCLM: 514/369.000
NCLS: 514/342.000
IC [6]
ICM: A61R031-425
EXF 514/342; 514/369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 47 OF 52 USPATFULL on STN
AN 1999:4694 USPATFULL
TI Sulfonylurea-glitazone combinations for diabetes
IN Whitcomb, Randall Wayne, Ann Arbor, MI, United States
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)
PI US 5859037 19990112
AI US 1997-970057 19971113 (8)
PRAI US 1997-38224P 19970219 (60)
DT Utility
FS Granted
LN.CNT 1902
INCL INCLM: 514/369.000
INCLS: 514/593.000; 514/866.000
NCL NCLM: 514/369.000
NCLS: 514/593.000; 514/866.000
IC [6]
ICM: A61K031-425
ICS: A61K031-175
EXF 514/369; 514/593; 514/866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 48 OF 52 USPATFULL on STN
AN 1998:119160 USPATFULL
TI Use of troglitazone and related compounds for the treatment of the climacteric symptoms
IN Urban, Randall J., Friendswood, TX, United States
Green, Allan, Galveston, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5814647 19980929
AI US 1997-811419 19970304 (8)
DT Utility
FS Granted
LN.CNT 1525
INCL INCLM: 514/369.000
INCLS: 514/252.000; 514/256.000; 514/342.000; 514/360.000; 514/375.000; 514/376.000
NCL NCLM: 514/369.000
NCLS: 514/252.050; 514/255.050; 514/256.000; 514/342.000; 514/360.000; 514/375.000; 514/376.000
IC [6]
ICM: A61K031-44
ICS: A61K031-425; A61K031-41
EXF 514/252; 514/256; 514/342; 514/360; 514/369; 514/375; 514/376
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 49 OF 52 USPATFULL on STN
AN 1998:98932 USPATFULL
TI DHA-pharmaceutical agent conjugates of taxanes
IN Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)
PI US 5795909 19980818
AI US 1996-651312 19960522 (8)
DT Utility
FS Granted

LN.CNT 2451
INCL INCLM: 514/449.000
INCLS: 514/549.000
NCL NCLM: 514/449.000
NCLS: 514/549.000
IC [6]
ICM: A61K031-335
ICS: A61K031-22
EXF 514/449; 514/549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 50 OF 52 USPATFULL on STN
AN 1998:54924 USPATFULL
TI Treatment and prophylaxis of pancreatitis
IN Fujiwara, Toshihiko, Ebina, Japan
Horikoshi, Hiroyoshi, Funabashi, Japan
Fukami, Masaharu, Yokohama, Japan
PA Sankyo Company, Limited, Tokyo, Japan (non-U.S. corporation)
PI US 5753681 19980519
AI US 1997-819686 19970317 (8)
PRAI JP 1996-61063 19960318
JP 1996-250201 19960920
DT Utility
FS Granted
LN.CNT 1149
INCL INCLM: 514/337.000
INCLS: 514/369.000; 514/370.000
NCL NCLM: 514/337.000
NCLS: 514/369.000; 514/370.000
IC [6]
ICM: A61K031-44
ICS: A61K031-425
EXF 514/337; 514/369; 514/370
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 51 OF 52 USPATFULL on STN
AN 97:12471 USPATFULL
TI Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
IN Antonucci, Tammy, Meguon, WI, United States
Lockwood, Dean, Ann Arbor, MI, United States
Norris, Rebecca, Kewadin, MI, United States
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)
PI US 5602133 19970211
AI US 1995-469398 19950606 (8)
RLI Division of Ser. No. US 1994-292585, filed on 23 Aug 1994, now patented, Pat. No. US 5457109 which is a continuation-in-part of Ser. No. US 1993-122251, filed on 15 Sep 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1639
INCL INCLM: 514/252.000
INCLS: 514/256.000; 514/342.000; 514/360.000; 514/369.000
NCL NCLM: 514/254.020
NCLS: 514/255.050; 514/256.000; 514/342.000; 514/360.000; 514/369.000
IC [6]
ICM: A61K031-425
ICS: A61K031-41; A61K031-44; A61K031-42
EXF 514/252; 514/256; 514/342; 514/360; 514/369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 52 OF 52 USPATFULL on STN
AN 95:90533 USPATFULL
TI Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

IN Antonucci, Tammy, Mequon, WI, United States
Lockwood, Dean, Ann Arbor, MI, United States
Norris, Rebecca, Kewadin, MI, United States
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)
PI US 5457109 19951010
AI US 1994-292585 19940823 (8)
RLI Continuation-in-part of Ser. No. US 1993-122251, filed on 15 Sep 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1416
INCL INCLM: 514/252.000
INCLS: 514/256.000; 514/342.000; 514/360.000; 514/309.000
NCL NCLM: 514/253.100
NCLS: 514/254.020; 514/256.000; 514/342.000; 514/360.000; 514/369.000
IC [6]
ICM: A61K031-425
ICS: A61K031-41; A61K031-44; A61K031-42
EXF 514/252; 514/256; 514/342; 514/360; 514/369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his

     (FILE 'HOME' ENTERED AT 13:29:57 ON 11 MAY 2005)

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:30:06 ON 11 MAY 2005

     FILE 'CAPLUS' ENTERED AT 13:30:46 ON 11 MAY 2005
L1            0 S S 122320-73-4/RN
L2         1131 S 122320-73-4/RN
L3          941 S 111025-46-8/RN
L4         1375 S 97322-87-7/RN
L5         3214 S L2 OR L3 OR L4 OR  NOSCAL OR REZULIN OR ROMGLIZONE OR TROGLIT
L6          415 S L5(L)( LEUKEM? OR CANCER? OR NEOPLAS? OR TUMOR? OR CARCINO? O
L7            4 S L6 NOT PY>=1997

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:36:14 ON 11 MAY 2005
L8           11 S L7
L9            5 DUP REM L8 (6 DUPLICATES REMOVED)

     FILE 'PROMT, IMSRESEARCH, IMSPRODUCT' ENTERED AT 13:43:06 ON 11 MAY 2005

     FILE 'PROMT, IMSRESEARCH, IMSPRODUCT' ENTERED AT 13:46:45 ON 11 MAY 2005
L10        1603 S NOSCAL OR REZULIN OR ROMGLIZONE OR TROGLITAZONE OR PIOGLITAZO
L11         288 S L10(L)( LEUKEM? OR CANCER? OR NEOPLAS? OR TUMOR? OR CARCINO?
L12         288 S L10(L)( LEUKEM? OR CANCER? OR NEOPLAS? OR TUMOR? OR CARCINO?
L13          12 S L12 NOT PY>=1996
L14          31 S L12 NOT PY>=1997
L15          31 DUP REM L14 (0 DUPLICATES REMOVED)

     FILE 'CAPLUS' ENTERED AT 13:57:50 ON 11 MAY 2005
L16         162 S 153559-49-0/RN

     FILE 'REGISTRY' ENTERED AT 13:58:37 ON 11 MAY 2005
L17           1 S 153559-49-0/RN
L18           1 S  153559-76-3/RN

     FILE 'CAPLUS' ENTERED AT 13:59:40 ON 11 MAY 2005
L19         259 S L17 OR L18 OR  LG(W)100268 OR  LGD(W)1268 OR  LG(W)268 OR  LG
L20          81 S L19(L)( LEUKEM? OR CANCER? OR NEOPLAS? OR TUMOR? OR CARCINO?
L21           4 S L20 NOT PY>=1997

     FILE 'EPFULL, FRFULL, GBFULL, PATDPAFULL, PCTFULL, RDISCLOSURE,
     USPATFULL, USPAT2' ENTERED AT 14:27:39 ON 11 MAY 2005
L22        3256 S L12
L23          15 S L22 NOT PY>1997
L24          15 DUP REM L23 (0 DUPLICATES REMOVED)

=>
```

L24 ANSWER 8 OF 15 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1996034943 PCTFULL ED 20020514
TITLE (ENGLISH): HUMAN LEUKOCYTE 12-LIPOXYGENASE AND ITS ROLE IN THE PATHOGENESIS OF DISEASE STATES
TITLE (FRENCH): 12-LIPOXYGENASE LEUCOCYTAIRE HUMAINE ET SON ROLE DANS LA PATHOGENESE D'ETATS PATHOLOGIQUES
INVENTOR(S): NADLER, Jerry, L.;
NATARAJAN, Rama
PATENT ASSIGNEE(S): CITY OF HOPE;
NADLER, Jerry, L.;
NATARAJAN, Rama
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9634943	A1	19961107

DESIGNATED STATES
W: AU CA JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1996-US6328 A 19960503
PRIORITY INFO.: US 1995-8/434,681 19950504

=> d ibib 1-5

L9 ANSWER 1 OF 5 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1996:506788 BIOSIS
DOCUMENT NUMBER: PREV199699229144
TITLE: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
AUTHOR(S): Dunaif, Andrea [Reprint author]; Scott, Denise; Finegood, Diane; Quintana, Benjamin; Whitcomb, Randall
CORPORATE SOURCE: Dep. Med., Melton S. Hershey Med. Cent., 500 University Dr., Room C-6630, Hershey, PA 17033-0850, USA
SOURCE: Journal of Clinical Endocrinology and Metabolism, (1996) Vol. 81, No. 9, pp. 3299-3306.
CODEN: JCEMAZ. ISSN: 0021-972X.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Nov 1996
Last Updated on STN: 14 Nov 1996

L9 ANSWER 2 OF 5 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1996:197933 BIOSIS
DOCUMENT NUMBER: PREV199698754062
TITLE: The thiazolidinedione drug series.
AUTHOR(S): Stevenson, Ralph W. [Reprint author]; Gibbs, E. Michael; Kreutter, David K.; McPherson, R. Kirk; Clark, David A.; Hulin, Bernard; Goldstein, Steven W.; Parker, Janice C.; Swick, Andrew G.; Treadway, Judith; Hargrove, Diane M.; Shulman, Gerald I.
CORPORATE SOURCE: Dep. Metab. Dis., Central Res. Div., Pfizer Inc., Eastern Point Road, Groton, CT 06340, USA
SOURCE: Marshall, S. M. [Editor]; Home, P. D. [Editor]; Rizza, R. A. [Editor]. Diabetes Annual, (1995) pp. 175-191. Diabetes Annual.
Publisher: Elsevier Science Publishers B.V., PO Box 211, Sara Burgerhartstraat 25, 1000 AE Amsterdam, Netherlands; Elsevier Science Publishing Co., Inc., P.O. Box 882, Madison Square Station, New York, New York 10159-2101, USA.
Series: Diabetes Annual.
ISSN: 0168-9282. ISBN: 0-444-82055-8.
DOCUMENT TYPE: Book
Book; (Book Chapter)
General Review; (Literature Review)
LANGUAGE: English
ENTRY DATE: Entered STN: 2 May 1996
Last Updated on STN: 2 May 1996

L9 ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 95203206 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7895657
TITLE: Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells.
AUTHOR: Szalkowski D; White-Carrington S; Berger J; Zhang B
CORPORATE SOURCE: Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065.
SOURCE: Endocrinology, (1995 Apr) 136 (4) 1474-81.
Journal code: 0375040. ISSN: 0013-7227.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199504
ENTRY DATE: Entered STN: 19950504
Last Updated on STN: 19950504
Entered Medline: 19950425

L9 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 95045256 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7956951
TITLE: Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells.
AUTHOR: Ohsumi J; Sakakibara S; Yamaguchi J; Miyadai K; Yoshioka S; Fujiwara T; Horikoshi H; Serizawa N
CORPORATE SOURCE: Biomedical Research Laboratories, Sankyo Co. Ltd., Tokyo, Japan.
SOURCE: Endocrinology, (1994 Nov) 135 (5) 2279-82.
Journal code: 0375040. ISSN: 0013-7227.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199412
ENTRY DATE: Entered STN: 19950110
Last Updated on STN: 19950110
Entered Medline: 19941216

L9 ANSWER 5 OF 5 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 94102197 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8275942
TITLE: Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.
AUTHOR: Hofmann C; Lorenz K; Braithwaite S S; Colca J R; Palazuk B J; Hotamisligil G S; Spiegelman B M
CORPORATE SOURCE: Research Service, Hines Veterans Administration Hospital, Illinois 60141.
SOURCE: Endocrinology, (1994 Jan) 134 (1) 264-70.
Journal code: 0375040. ISSN: 0013-7227.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199402
ENTRY DATE: Entered STN: 19940218
Last Updated on STN: 19940218
Entered Medline: 19940207

L15 ANSWER 20 OF 31 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 95:141561 PROMT
TITLE: Atorvastatin Superior To Other Statins?
SOURCE: Marketletter, (24 Apr 1995) pp. N/A.
ISSN: 0140-4288.
LANGUAGE: English
WORD COUNT: 267
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Parke-Davis' HMG-CoA reductase inhibitor atorvastatin has outperformed other statin drugs in head-to-head comparative studies, according to company chairman Ronald Cresswell at an analysts' briefing in New York, USA.

Atorvastatin, at a dose of 10mg, is more effective in reducing serum lipids than all the other available statins at their highest approved doses, said Dr Cresswell. The drug lowers low-density lipoprotein cholesterol by as much as 60%, triglycerides by as much as 40%, and raises beneficial high-density lipoprotein cholesterol by around 12%.

Dr Cresswell predicted that a New Drug Application for atorvastatin would be filed in the middle of next year, and the company hopes to achieve sales of $800 million a year at peak. The company expects to build on the lipid -lowering franchise it has achieved with its Lopid (gemfibrozil) range of products.

Pipeline Prospects Also highlighted at the briefing was a new diabetes therapy, troglitazone, which has an NDA submission scheduled for December 1996. Parke-Davis parent company Warner-Lambert licenses this drug from Japan's Sankyo, while Glaxo holds European rights. The three companies are sharing clinical data. Dr Cresswell noted that the drug appears to lower insulin resistance without impairing gluconeogenesis in the liver. Peak North American sales have been estimated at $400 million, according to the company.

L21 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:2622 CAPLUS
DOCUMENT NUMBER: 126:54540
TITLE: Chemoprevention of mammary **carcinoma** by LGD1069 (**Targretin**): an RXR-selective ligand
AUTHOR(S): Gottardis, Marco M.; Bischoff, Eric D.; Shirley, Michael A.; Wagoner, Murriel A.; Lamph, William W.; Heyman, Richard A.
CORPORATE SOURCE: Dep. Endocrine Res., Ligand Pharm., Inc., San Diego, CA, 92121, USA
SOURCE: Cancer Research (1996), 56(24), 5566-5570
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To explore the specific contribution that retinoid X-receptor (RXR) activation may play in suppression of **carcinogenesis**, the efficacy of LGD1069 (**Targretin**), an RXR-selective ligand, in the N-nitroso-N-methylurea-induced rat mammary **tumor** model was studied. LGD1069-treated animals showed a 90% reduction in **tumor** burden and **tumor** incidence compared with vehicle-treated rats, a drug efficacy similar to that achieved with tamoxifen. LGD1069 was very well tolerated during 13 wk of chronic therapy, with no classic signs of retinoid-associated toxicities. Thus, LGD1069, an RXR-selective ligand, can act as a highly effective and benign chemopreventive agent for mammary **carcinoma**.